sur TuHURA Biosciences, Inc.
TuHURA Biosciences to Present at ROTH Conference
TuHURA Biosciences, Inc. (NASDAQ:HURA), an immuno-oncology firm, announced participation in the 37th Annual ROTH Conference. James A. Bianco, CEO, will engage in a fireside chat on March 18, 2025, at 8:30 AM PT in Dana Point, CA. The event includes opportunities for one-on-one investor meetings. Further details are available on the conference website.
A live webcast of the discussion will be accessible via the company's website. TuHURA, currently in Phase 3 of registering its immune technology, is developing solutions to combat resistance in cancer immunotherapy.
The firm prepares to launch a Phase 3 trial for its drug IFx-2.0 against Merkel Cell Carcinoma. TuHURA also advances a VISTA inhibiting antibody, following a merger with Kineta, for AML treatment. Research on the Delta Opioid Receptor's immune role is underway.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TuHURA Biosciences, Inc.